Eli Lilly says a longer-lasting version of its best-selling drug Zyprexa delivers a low rate of relapse or discontinuation among schizophrenics.
Lilly spokesman Charles McAtee says the long-acting injectable form of Zyprexa shows a relapse rate comparable to the pill version of the anti-psychotic currently being sold by the Indianapolis company. The new version still must be approved by federal regulators.
A total of 1,065 patients participated in the study, and McAtee did not know the percentage who relapsed. But he said the point of the study was to see whether the long-acting Zyprexa was comparable to the pill version.
Indianapolis-based Lilly presented results of the 24-week study at a medical conference in Barcelona, Spain.
(Copyright 2008 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)
Lilly: Long-acting Zyprexa shows low relapse rate
We've upgraded our reader commenting system. Learn more about the new features.
Having technical problems? Check here for guidance.